- ECHA
- Konsultācijas
- Mērķtiecīgas konsultācijas par saskaņotu klasificēšanu un marķēšanu
- Harmonised classification and labelling previous targeted consultations
Harmonised classification and labelling previous targeted consultations
Harmonised classification and labelling previous targeted consultations
These targeted consultations for CLH proposals are closed. The consultations are launched in case further information is needed on a particular hazard class, or if comments are sought on e.g. a specific additional document.
The comments received during the consultation are available on the Registry of CLH intentions until outcome.
There are currently no ongoing consultations.
Rāda 41 rezultātus.
(RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate; tolpyralate | - | 1101132-67-5 | United Kingdom |
Carc. 2, H351 STOT RE 2, H373 Aquatic Acute 1, H400, M = 10 Aquatic Chronic 1, H410, M=100 |
Details | ||
1-isopropyl-4-methylbenzene; p-cymene | 202-796-7 | 99-87-6 | Netherlands |
Flam. Liq. 3, H226, Acute Tox. 3, H331, Asp. Tox. 1, H304, Aquatic Acute 1, H400, Aquatic Acute 1, M-factor=1, Aquatic Chronic 3, H412 |
Details | ||
2-butoxyethanol; ethylene glycol monobutyl ether | 203-905-0 | 111-76-2 | 603-014-00-0 | Article 77(3) request |
Acute Tox. 4*; H332 Acute Tox. 4*; H312 Acute Tox. 4*; H302 Skin Irrit. 2; H315 Eye Irrit. 2; H319 |
Acute Tox. 3; H331 Acute Tox. 4; H302 Skin Irrit. 2; H315 Eye Irrit. 2; H319 inhalation: ATE = 3 mg/L oral: ATE = 1200 mg/kg bw |
Details |
3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol | 211-477-1 | 647-42-7 | Germany |
STOT RE2, H373 (skeletal system) Aquatic Chronic 2, H411 |
Details | ||
3,4-dimethyl-1H-pyrazole | 429-130-1 | 2820-37-3 | 613-248-00-5 | Belgium |
Acute Tox. 4*, H302, Eye Dam. 1, H318, Aquatic Chronic 3, H412 |
Acute Tox. 4, H302, Acute Tox. 4, H312, Acute Tox. 4, H332, Eye Dam. 1, H318, Carc. 2, H351, Repr. 2, H361f, STOT RE 2, H373, Aquatic Chronic 3, H412 ATE (oral): 500 mg/kg bw ATE (dermal): 1100 mg/kg bw ATE (inhalation): 2.1 mg/l H373 (nasal cavity) |
Details |
3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate | 259-627-5 | 55406-53-6 | 616-212-00-7 | Denmark |
Acute Tox. 3, H331 Acute Tox. 4, H302, STOT RE 1, H372 (larynx) Eye Dam. 1, H318, Skin Sens. 1, H317, Aquatic Acute 1, H400, M = 10, Aquatic Chronic 1, H410, M = 1 |
Acute Tox. 2, H330, Acute Tox. 4, H302, STOT RE 1, H372 (larynx) Eye Dam. 1, H318, Skin Sens. 1, H317, Aquatic Acute 1, H400, M = 10, Aquatic Chronic 1, H410, M = 10 |
Details |
butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime | 202-496-6 | 96-29-7 | Germany |
Acute Tox. 4*, H312, Eye Dam. 1, H318, Skin Sens. 1, H317, Carc. 2, H351 |
Acute Tox. 3, H301, Acute Tox. 4, H312, Eye Dam. 1, H318, Skin Sens. 1B, H317, Carc. 1B, H350, STOT SE 3, H336 dermal: ATE = 1848 mg/kg oral: ATE = 100 mg/kg |
Details | |
Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with hydrocarbon solvents and Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with supercritical carbon dioxide | 289-699-3 | 89997-63-7 | Spain |
Acute Tox. 4, H302, Acute Tox. 4, H332, Skin Sens. 1B, H317, Aquatic Acute 1, H400, M-factor=100, Aquatic Chronic 1, H410, M-factor=10 ATE oral = 700 mg/kg bw ATE inhalation = 2.5 mg/L (dusts and mists) |
Details | ||
clethodim (ISO); (5RS)-2-{(1EZ)-1-[(2E)-3-chloroallyloxyimino]propyl}-5-[(2RS)-2-(ethylthio)propyl]-3-hydroxycyclohex-2-en-1-one | - | 99129-21-2 | Sweden | Acute Tox. 4, H302, Skin Sens. 1, H317, Aquatic Chronic 3, H412 EUH066 |
Self-react. G, Acute Tox. 4, H302, ATE = 1133 mg/kg bw, Skin Sens. 1, H317, STOT RE 2, H373, Aquatic Acute 1, H400, M-factor=10, Aquatic Chronic 1, H410, M-factor=10, EUH066 |
Details | |
clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one | 617-258-0 | 81777-89-1 | Denmark |
Acute Tox. 4, H302, Acute Tox. 4, H332, Repr. 1B, H360D, Aquatic Acute 1, H400, Aquatic Acute 1, M-factor=1, Aquatic Chronic 1, H410, Aquatic Chronic 1, M-factor=1 |
Details | ||
Copper compounds | - | - | M-factors for long-term aquatic hazard | Details | |||
cypermethrin (ISO); α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60 | 257-842-9 | 52315-07-8 | 607-421-00-4 | Belgium |
Acute Tox. 4*, H332 Acute Tox. 4*, H302 STOT SE 3, H335 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 |
Acute Tox. 4*, H332 Acute Tox. 4*, H302 STOT SE 3, H335 Aquatic Acute 1, H400 (M=100000) Aquatic Chronic 1, H410 (M=1000) |
Details |
daminozide (ISO); 4-(2,2-dimethylhydrazino)-4-oxobutanoic acid; N-dimethylaminosuccinamic acid | 216-485-9 | 1596-84-5 | Czech Republic | Carc. 1B, H350 | Details | ||
diflufenican (ISO); N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide | 617-446-2 | 83164-33-4 | 616-032-00-9 | United Kingdom | Aquatic Chronic 3, H412 |
Aquatic Acute 1, H400 Aquatic Chronic 1, H410 |
Details |
Flumioxazin (ISO),N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboxamide | - | 103361-09-7 | 613-166-00-X | Czech Republic |
Repr. 1B, H360D, Aquatic Acute 1, H400, Aquatic Acute 1, M-factor=1000, Aquatic Chronic 1, H410, Aquatic Chronic 1, M-factor=1000 |
Repr. 2, H361d, Aquatic Acute 1, H400, Aquatic Acute 1, M-factor=1000, Aquatic Chronic 1, H410, Aquatic Chronic 1, M-factor=1000 |
Details |
Glyphosate | 213-997-4 | 1071-83-6 | 607-315-00-8 | Sweden |
Eye Dam. 1, H318, Aquatic Chronic 2, H411 |
Eye Dam. 1, H318, Aquatic Chronic 2, H411 |
Details |
hexyl 2-(1-(diethylaminohydroxyphenyl)methanoyl)benzoate; hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate | 443-860-6 | 302776-68-7 | 607-693-00-4 | Germany | Aquatic Chronic 4, H413 | Aquatic Chronic 1, H410, M-factor = 1000 | Details |
Hexyl salicylate | 228-408-6 | 6259-76-3 | France |
Skin Sens. 1, H317, Repr. 2, H361d |
Details | ||
lead | 231-100-4 | 7439-92-1 |
082-013-00-1 082-014-00-7 |
Article 77(3) request |
Repr. 1A, H360FD Lact., H362 |
Repr. 1A, H360FD Lact., H362 Aquatic Acute 1, H400; M=1 Aquatic Chronic 1, H410; M=10 |
Details |
lithium carbonate [1] lithium chloride [2] lithium hydroxide [3] |
209-062-5 231-212-3 215-183-4 |
554-13-2 7447-41-8 1310-65-2 |
France | Repr. 1A, H360FD | Details | ||
lithium carbonate [1] lithium chloride [2] lithium hydroxide [3] |
209-062-5 231-212-3 215-183-4 |
554-13-2 7447-41-8 1310-65-2 |
TBD | Article 77(3) request |
Repr. 1A, H360FD Lact., H362 |
Details | |
MCPA-thioethyl (ISO); S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate | 246-831-4 | 25319-90-8 | 246-831-4 | Poland |
Acute Tox. 4, H302, Aquatic Acute 1, M-factor=10, Aquatic Chronic 1, M-factor=10 |
Details | |
Melaleuca alternifolia, ext. Melaleuca alternifolia, essential oil; tea tree oil | 285-377-1 |
85085-48-9 68647-73-4 |
Poland |
Flam. Liq. 3, H226, Acute Tox. 4, H302, oral: ATE = 1049 mg/kg bw Acute Tox. 4, H332, inhalation: ATE = 3.64 mg/L (mist) Skin Irrit. 2, H315, Skin Sens. 1B, H317, Repr. 2, H361f, Asp. Tox. 1, H304, Aquatic Acute 1, H400, M-factor=1, Aquatic Chronic 3, H412 |
Details | ||
methyl methacrylate methyl 2-methylprop-2-enoate methyl 2-methylpropenoate | 201-297-1 | 80-62-6 | 607-035-00-6 | France |
Flam. Liq. 2, H225 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335 |
Flam. Liq. 2, H225 Skin Irrit. 2, H315 Resp. Sens. 1, H334 Skin Sens. 1, H317 STOT SE 3, H335 |
Details |
methyl methacrylate; methyl 2-methylprop-2-enoate; methyl 2-methylpropenoate | 201-297-1 | 80-62-6 | 607-035-00-6 | Article 77(3) request |
Flam. Liq. 2, H225 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335 |
Flam. Liq. 2, H225 Resp. Sens. 1, H 334 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335 |
Details |
metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one | 244-209-7 | 21087-64-9 | 606-034-00-8 | Estonia |
Acute Tox. 4*, H302, Aquatic Acute 1, H400, Aquatic Acute 1, M-factor=10, Aquatic Chronic 1, H410, Aquatic Chronic 1 |
Acute Tox. 4, H302, STOT RE 2, H373, Aquatic Acute 1, H400, Aquatic Acute 1, M-factor=10, Aquatic Chronic 1, H410, Aquatic Chronic 1, M-factor=100 ATE 322 mg/kg bw |
Details |
metyltetraprole (ISO); 1-[2-({[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy}methyl)-3-methylphenyl]-4-methyl-1,4-dihydro-5H-tetrazol-5-one | - | 1472649-01-6 | France |
Carc. 2, H351, Aquatic Acute 1, H400, M = 10, Aquatic Chronic 1, H410, M = 1 |
Details | ||
N(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine | 212-344-0 | 793-24-8 | Austria |
Acute Tox. 4, H302, Skin Sens. 1A, H317, Repr. 1B, H360FD, Aquatic Acute 1, H400, M-factor=10 000, Aquatic Chronic 1, H410, M-factor=10 Oral: ATE = 890 mg/kg bw |
Details | ||
N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram | - | 1255734-28-1 | United Kingdom |
Acute Tox. 4, H332, Skin Sens. 1B, H317, Aquatic Acute 1, H400, Aquatic Acute 1, M-factor=10, Aquatic Chronic 1, H410, Aquatic Chronic 1, M-factor=1 ATE = 2.2 mg/L |
Details | ||
N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA] | 213-103-2 | 924-42-5 | France |
Muta. 1B, H340, Carc. 1B, H350, STOT RE 1, H372 |
Details | ||
N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid); Pentapotassium 2,2',2'',2''',2''''-(ethane-1,2-diylnitrilo)pentaacetate; Pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate |
200-652-8 404-290-3 205-391-3 |
67-43-6 7216-95-7 140-01-2 |
Commission | Details | |||
pendimethalin (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidene | 254-938-2 | 40487-42-1 | 609-042-00-X | Netherlands |
Skin Sens. 1; H317 Aquatic Acute 1; H400 Aquatic Chronic 1; H410 |
Repr. 2; H361d Skin Sens. 1B; H317 Aquatic Acute 1; H400 (M=100) Aquatic Chronic 1; H410 (M=10) |
Details |
prothioconazole (ISO); 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione | - | 178928-70-6 | United Kingdom |
Aquatic Acute 1, H400, Aquatic Chronic 1, H410 |
Details | ||
pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc | 236-671-3 | 13463-41-7 | Sweden |
Acute Tox. 3, H301, Acute Tox. 2, H330, Eye Dam. 1, H318, Repr. 1B, H360D, STOT RE 1, H372, Aquatic Acute 1, H400, M-factor=1000, Aquatic Chronic 1, H410, M-factor=10 |
Details | ||
pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc | 236-671-3 | 13463-41-7 | Sweden |
Acute Tox. 3, H301 Acute Tox. 2, H330 Eye Dam. 1, H318 Repr. 1B, H360D STOT RE 1, H372 Aquatic Acute 1, H400 Aquatic Acute 1, M-factor=1000 Aquatic Chronic 1, H410 Aquatic Chronic 1, M-factor=10 |
Details | ||
S-metolachlor (ISO); 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide; (RaSa)-2-chloro-N-(6-ethyl-o-tolyl)-N-[(1S)-2-methoxy-1-methylethyl]acetamide [contains 80-100 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2R)-1-methoxypropan-2-yl]acetamide] | - | 87392-12-9 | 607-432-00-4 | Germany |
Skin Sens. 1; H317 Aquatic Acute 1; H400 Aquatic Chronic 1; H410 |
Carc. 2; H351 Repr. 2; H361d STOT RE 2; H373 (skin) Skin Sens. 1; H317 Aquatic Acute 1 H400 (M=10) Aquatic Chronic 1 H410 (M=10) |
Details |
Silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica | 272-697-1 | 68909-20-6 | 014-052-00-7 | Article 77(3) request | STOT RE 2, H373 (lungs, inhalation) |
Acute Tox. 2, H330 STOT RE 2, H373 (lungs, inhalation) inhalation: ATE = 0,45 mg/L |
Details |
Silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica | 272-697-1 | 68909-20-6 | France | STOT RE 2, H373; Acute Tox. 2, H330 ATE = 0.45 mg/L (dusts and mists) | Details | ||
Silver | 231-131-3 | 7440-22-4 | Sweden |
Skin Sens. 1, H317, Muta. 2, H341, Repr. 1B, H360FD, Aquatic Acute 1, H400, M-factor=10 (for silver), Aquatic Acute 1, H400, M-factor=1000 (for nano silver), Aquatic Chronic 1, H410, M-factor=10 (for silver), Aquatic Chronic 1, H410, M-factor=100 (for nano silver) |
Details | ||
Silver | 231-131-3 | 7440-22-4 | Sweden |
Skin Sens. 1, H317, Muta. 2, H341, Repr. 1B, H360FD, Aquatic Acute 1, H400, M-factor=10 (for silver), Aquatic Acute 1, H400, M-factor=1000 (for nano silver), Aquatic Chronic 1, H410, M-factor=10 (for silver), Aquatic Chronic 1, H410, M-factor=100 (for nano silver) |
Details | ||
transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate | 405-060-5 | 118712-89-3 | 607-223-00-8 | Netherlands |
Skin Irrit. 2, H315 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 |
Acute Tox. 4, H302 Carc. 2, H351 STOT SE 1, H370 STOT RE 2, H373 Aquatic Acute 1, H400, M-factor=1000 Aquatic Chronic 1, H410, M-factor=1000 oral: ATE = 583 mg/kg bw |
Details |
Rāda 41 rezultātus.